The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of multimodality treatment (MT) with improved overall survival (OS) in patients (pts) with advanced/metastastic soft tissue sarcoma (a/m STS).
 
Philipp Ivanyi
No Relationships to Disclose
 
Katharina Stange
No Relationships to Disclose
 
Hendik Eggers
No Relationships to Disclose
 
Christoph W. Reuter
No Relationships to Disclose
 
Martin Panzica
No Relationships to Disclose
 
Patrick Zardo
No Relationships to Disclose
 
Florain Länger
No Relationships to Disclose
 
Hans Christiansen
No Relationships to Disclose
 
Arnold Ganser
No Relationships to Disclose
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; MSD
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Cerulean Pharma; ClinSol; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer